{"id":"https://openalex.org/W7214826548","doi":null,"title":"Efficacy and Safety of Recently Approved Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Meta-Analysis","display_name":"Efficacy and Safety of Recently Approved Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Meta-Analysis","publication_year":2026,"publication_date":"2026-08-19","ids":{"openalex":"https://openalex.org/W7214826548"},"language":"en","primary_location":{"id":"pmh:oai:ojs.www.ijms.info:article/4799","doi":null,"is_oa":true,"landing_page_url":"https://ijms.info/IJMS/article/view/4799","pdf_url":"https://ijms.info/IJMS/article/download/4799/3423","source":{"id":"https://openalex.org/S2765068989","display_name":"International Journal of Medical Students","issn_l":"2076-6327","issn":["2076-6327"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310315549","host_organization_name":"International Journal of Medical Students","host_organization_lineage":["https://openalex.org/P4310315549"],"host_organization_lineage_names":["International Journal of Medical Students"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"2076-6327","raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://ijms.info/IJMS/article/download/4799/3423","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5121693101","display_name":"Hassan Khalid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I7848551","display_name":"Tbilisi State Medical University","ror":"https://ror.org/020jbrt22","country_code":"GE","type":"education","lineage":["https://openalex.org/I7848551"]}],"countries":["GE"],"is_corresponding":false,"raw_author_name":"Khalid, Hassan","raw_affiliation_strings":["Tbilisi State Medical University, Tbilisi, Georgia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tbilisi State Medical University, Tbilisi, Georgia","institution_ids":["https://openalex.org/I7848551"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043634791","display_name":"Mohammed Murtada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I7848551","display_name":"Tbilisi State Medical University","ror":"https://ror.org/020jbrt22","country_code":"GE","type":"education","lineage":["https://openalex.org/I7848551"]}],"countries":["GE"],"is_corresponding":false,"raw_author_name":"Murtada, Mohammed","raw_affiliation_strings":["Tbilisi State Medical Univeristy, Tbilisi, Georgia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tbilisi State Medical Univeristy, Tbilisi, Georgia","institution_ids":["https://openalex.org/I7848551"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I7848551"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.62979755,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.023099999874830246,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9670000076293945},{"id":"https://openalex.org/keywords/lecanemab","display_name":"lecanemab","score":0.8500000238418579},{"id":"https://openalex.org/keywords/donanemab","display_name":"donanemab","score":1.0},{"id":"https://openalex.org/keywords/anti-amyloid-monoclonal-antibodies","display_name":"anti-amyloid monoclonal antibodies","score":0.996999979019165},{"id":"https://openalex.org/keywords/amyloid-plaques","display_name":"amyloid plaques","score":0.9290000200271606},{"id":"https://openalex.org/keywords/amyloid-related-imaging-abnormalities","display_name":"amyloid-related imaging abnormalities","score":0.9739999771118164},{"id":"https://openalex.org/keywords/cognitive-decline","display_name":"cognitive decline","score":0.7110000252723694},{"id":"https://openalex.org/keywords/functional-decline","display_name":"functional decline","score":0.753000020980835},{"id":"https://openalex.org/keywords/early-alzheimer-s-disease","display_name":"early Alzheimer's disease","score":0.7749999761581421},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5540000200271606},{"id":"https://openalex.org/keywords/placebo-controlled-comparison","display_name":"placebo comparison","score":0.38600000739097595}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8256999850273132},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6722000241279602},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5799000263214111},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5091999769210815},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.5002999901771545},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.45899999141693115},{"id":"https://openalex.org/C2984863031","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Cognitive decline","level":4,"score":0.4433000087738037},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.4309999942779541},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.41679999232292175},{"id":"https://openalex.org/C2984915365","wikidata":"https://www.wikidata.org/wiki/Q5141203","display_name":"Cognitive impairment","level":3,"score":0.38830000162124634},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3736000061035156},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.37290000915527344},{"id":"https://openalex.org/C189708586","wikidata":"https://www.wikidata.org/wiki/Q1504425","display_name":"Systematic review","level":3,"score":0.3427000045776367},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3084000051021576},{"id":"https://openalex.org/C160798450","wikidata":"https://www.wikidata.org/wiki/Q4230870","display_name":"Concordance","level":2,"score":0.3019999861717224},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.29600000381469727},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.29440000653266907},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.28060001134872437},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.262800008058548},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.2587999999523163},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.2556999921798706},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.25459998846054077},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.25360000133514404},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.250900000333786},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2500999867916107}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:ojs.www.ijms.info:article/4799","doi":null,"is_oa":true,"landing_page_url":"https://ijms.info/IJMS/article/view/4799","pdf_url":"https://ijms.info/IJMS/article/download/4799/3423","source":{"id":"https://openalex.org/S2765068989","display_name":"International Journal of Medical Students","issn_l":"2076-6327","issn":["2076-6327"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310315549","host_organization_name":"International Journal of Medical Students","host_organization_lineage":["https://openalex.org/P4310315549"],"host_organization_lineage_names":["International Journal of Medical Students"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"2076-6327","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:ojs.www.ijms.info:article/4799","doi":null,"is_oa":true,"landing_page_url":"https://ijms.info/IJMS/article/view/4799","pdf_url":"https://ijms.info/IJMS/article/download/4799/3423","source":{"id":"https://openalex.org/S2765068989","display_name":"International Journal of Medical Students","issn_l":"2076-6327","issn":["2076-6327"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310315549","host_organization_name":"International Journal of Medical Students","host_organization_lineage":["https://openalex.org/P4310315549"],"host_organization_lineage_names":["International Journal of Medical Students"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"2076-6327","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214826548.pdf","grobid_xml":"https://content.openalex.org/works/W7214826548.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7212248893","https://openalex.org/W7165664571","https://openalex.org/W4409516484","https://openalex.org/W7204889216","https://openalex.org/W7130518567","https://openalex.org/W7214664211","https://openalex.org/W7214750829","https://openalex.org/W7221847606","https://openalex.org/W7140303382","https://openalex.org/W7164149535"],"abstract_inverted_index":{"Background:":[0],"Alzheimer's":[1],"disease":[2,457],"(AD)":[3],"is":[4],"the":[5,26,33,48,61,65,80,188,212,248,331,351,356,437,465],"leading":[6],"cause":[7],"of":[8,44,50,67,84,110,139,183,198,229,250,269,372,390,439],"dementia":[9],"worldwide":[10],"and":[11,18,57,60,82,86,103,135,167,176,193,209,221,284,310,366,387,420,425,470],"affects":[12],"over":[13,247],"55":[14],"million":[15],"people.":[16],"Lecanemab":[17],"donanemab":[19,87,156,296,360,421],"are":[20],"anti-amyloid":[21],"monoclonal":[22,237],"antibodies":[23,238],"that":[24],"flag":[25],"abnormal":[27],"amyloid-beta":[28],"plaques":[29],"for":[30,467],"removal":[31],"by":[32,261,305,313,347,363],"immune":[34],"system.":[35],"Recent":[36],"phase":[37],"3":[38,215],"trials":[39,216],"have":[40],"demonstrated":[41,194],"significant":[42],"slowing":[43,268],"clinical":[45,51,241,462],"decline.":[46,270],"However,":[47],"magnitude":[49],"benefit,":[52],"comparative":[53],"efficacy":[54,81],"across":[55,200],"cognitive":[56,99,179,424],"functional":[58,426],"domains,":[59],"safety":[62,83],"profile":[63],"including":[64],"incidence":[66],"amyloid-related":[68,379],"imaging":[69,380],"abnormalities":[70],"(ARIA)":[71],"require":[72],"pooled":[73],"quantitative":[74],"synthesis.":[75],"Objective:":[76],"To":[77],"quantitatively":[78],"synthesise":[79],"lecanemab":[85,154,220,257,344,419],"against":[88],"placebo":[89,246],"in":[90,164,330,370,384,456],"patients":[91,319,392,414],"with":[92,95,150,219,224,232,320,415],"early":[93,151,233,416],"AD,":[94],"a":[96,195,227,266,278,407,452],"focus":[97],"on":[98,131,162,178,282,288,341,396],"outcomes,":[100],"amyloid":[101,173,338,368,431],"clearance,":[102],"ARIA":[104,168,410,442],"incidence.":[105,169],"Methods:":[106],"A":[107],"systematic":[108,207],"search":[109],"reputable":[111],"electronic":[112],"databases":[113,140],"was":[114,185],"conducted":[115,130],"predefined":[116],"keywords:":[117],"\u201cAlzheimer":[118],"disease\u201d,":[119],"\u201cdementia\u201d,":[120],"\u201clecanemab\u201d,":[121],"\u201cdonanemab\u201d,":[122],"\u201canti-amyloid":[123],"antibody\u201d,":[124],"\u201cCDR-SB\u201d,":[125],"\u201cARIA\u201d.":[126],"All":[127],"searches":[128],"were":[129,327,400],"January":[132,142],"5,":[133],"2026":[134],"ranged":[136],"from":[137],"inception":[138],"to":[141,245,265,322,473,478],"2026.":[143],"Eligible":[144],"studies":[145],"included":[146,172,211],"RCTs":[147],"involving":[148,226],"adults":[149],"AD":[152,218,255],"receiving":[153],"or":[155],"versus":[157,393],"placebo.":[158,397],"Primary":[159],"outcomes":[160,171,272],"focused":[161],"changes":[163],"CDR-SB":[165,259,311],"score":[166],"Secondary":[170,271],"PET":[174,342],"clearance":[175,369],"performance":[177],"subscales":[180],"(ADAS-Cog).":[181],"Risk":[182],"bias":[184,199],"assessed":[186],"using":[187],"Cochrane":[189],"RoB":[190],"2.0":[191],"tool":[192],"low":[196,321],"risk":[197],"all":[201],"five":[202],"methodological":[203],"domains.":[204],"Results:":[205],"Our":[206],"review":[208],"meta-analysis":[210],"two":[213],"Phase":[214],"(CLARITY":[217],"TRAILBLAZER-ALZ":[222,293],"2":[223,294],"donanemab)":[225],"total":[228],"3531":[230],"participants":[231],"Alzheimer\u2019s":[234,417],"disease.":[235],"Anti-amyloid":[236],"consistently":[239],"showed":[240,273,377],"decline":[242,304,427],"when":[243],"compared":[244],"span":[249],"18":[251],"months.":[252],"In":[253,292,413],"CLARITY":[254],"(n=1795),":[256],"reduced":[258,361],"worsening":[260],"0.45":[262],"points,":[263],"parallel":[264],"27%":[267],"similar":[274,329],"benefits,":[275],"such":[276],"as":[277],"1.44":[279],"-point":[280],"advantage":[281],"ADAS-Cog14":[283],"improved":[285],"daily":[286],"functioning":[287],"ADCS-MCI-ADL":[289],"(+2.0":[290],"points).":[291],"(n=1736),":[295],"produced":[297,367],"comparable":[298],"effects.":[299],"The":[300],"drug":[301],"slowed":[302],"iADRS":[303],"3.25":[306],"points":[307,315],"(35.1%":[308],"slowing)":[309],"progression":[312],"0.67":[314],"(36%":[316],"slowing),":[317],"among":[318,445],"medium":[323],"tau":[324],"pathology.":[325],"Benefits":[326],"somewhat":[328],"overall":[332],"population.":[333],"Both":[334],"agents":[335],"achieved":[336],"substantial":[337],"plaque":[339],"reduction":[340],"imaging:":[343],"lowered":[345],"levels":[346],"59.12":[348],"centiloids,":[349],"lowering":[350],"mean":[352],"post-treatment":[353],"burden":[354],"below":[355],"positivity":[357],"threshold,":[358],"while":[359,428],"centiloids":[362],"approximately":[364],"87-88":[365],"76-80%":[371],"treated":[373,391],"patients.":[374],"Safety":[375],"findings":[376],"increased":[378],"abnormalities.":[381],"ARIA-E":[382],"occurred":[383],"12.6%":[385],"(lecanemab)":[386],"24%":[388],"(donanemab)":[389],"roughly":[394],"2%":[395],"ARIA-H":[398],"rates":[399],"similarly":[401],"elevated.":[402],"APOE":[403,446],"\u03b54":[404,447],"carriers":[405],"faced":[406],"significantly":[408,440],"higher":[409],"risk.":[411],"Conclusion:":[412],"disease,":[418],"moderately":[422],"slow":[423],"producing":[429],"strong":[430],"clearance.":[432],"These":[433,449],"benefits":[434],"come":[435],"at":[436],"cost":[438],"elevated":[441],"risk,":[443],"especially":[444],"carriers.":[448],"therapies":[450],"represent":[451],"meaningful":[453],"first":[454],"step":[455],"modification,":[458],"yet":[459],"their":[460],"modest":[461],"effects":[463],"highlight":[464],"need":[466],"longer-term":[468],"data":[469],"better":[471],"strategies":[472],"identify":[474],"those":[475],"most":[476],"likely":[477],"benefit.":[479]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-09-30T00:00:00"}